TEVA-ALFUZOSIN PR TABLET (EXTENDED-RELEASE)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ALFUZOSIN HYDROCHLORIDE

可用日期:

TEVA CANADA LIMITED

ATC代码:

G04CA01

INN（国际名称）:

ALFUZOSIN

剂量:

10MG

药物剂型:

TABLET (EXTENDED-RELEASE)

组成:

ALFUZOSIN HYDROCHLORIDE 10MG

给药途径:

ORAL

每包单位数:

30/100

处方类型:

Prescription

治疗领域:

Selective Alfa-1-Adrenergic Blocking Agents

產品總結:

Active ingredient group (AIG) number: 0146806001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2018-05-02

产品特点

1
PRODUCT MONOGRAPH
PR
TEVA-ALFUZOSIN PR
Alfuzosin Hydrochloride
Prolonged-Release Tablets 10 mg
Pharmaceutical standard: Professed
SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Preparation:
May 31, 2011
Control No.: 147134
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
6
DRUG INTERACTIONS
...........................................................................................................
9
DOSAGE AND
ADMINISTRATION.....................................................................................
12
OVERDOSAGE
.......................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 13
STORAGE AND
STABILITY.................................................................................................
18
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 18
PART II: SCIENTIFIC INFORMATION
...............................................................................
19
PHARMACEUTICAL
INFO